AI in Personalized Cancer Medicine: New Therapies Require Flexible and Safe Approval Conditions

The application of AI in precision oncology has so far been largely confined to the development of new drugs and had only limited impact on the personalisation of therapies. New AI-based approaches are increasingly being applied to the planning and implementation of personalised drug and cell therapies. Therapies can be adapted to individual patients' needs - for example to improve efficacy and dosage, reduce toxicity, develop combination therapies and even personalise preclinical cell therapies regarding their molecular properties.

AI-based healthcare is developing continuously and with increasing speed. It can support doctors with decision-making and therapy planning as well as in early multi-cancer precision diagnostics. Other potential applications include the design of new types of personalised medical products, drug companion apps for patients and the use of so-called "digital twins". The latter use patient data in almost real-time to enable more precise diagnosis by means of simulation and modelling and to adapt treatments to individual requirements. Advancing these products through regulatory pathways is enormously challenging. They combine technologies governed by different legal frameworks and regulatory bodies and are so novel that they are not well dealt with in current legislation. It can already be anticipated that the current approval conditions will make rapid clinical application difficult.

Making approval processes more agile in the future

The publication identifies two large challenges: legislators and regulatory bodies underestimate the importance of the developing technologies in this area as well as the extent of required regulatory change to make approval processes more agile in the future. "The current regulations are a de facto blocker to AI-based personalised medicine. A fundamental change is needed to solve this problem," says Stephen Gilbert, Professor of Medical Device Regulatory Science at the Else Kröner Fresenius Center for Digital Health at TU Dresden and University Hospital Carl Gustav Carus Dresden. The researchers therefore suggest, among other things, updating risk-benefit assessments for highly personalised treatment approaches. Solutions already established in the US could also be adopted in the EU for certain classes of low-risk decision support for doctors. The authors further suggest approaches to allow digital tools on market to be safety adaptable in a more flexible manner and to establish suitable test platforms for on-market monitoring. Multi-layered approaches would help to spread the load of oversight and make evaluation more relevant to patient safety.

Employees from the following institutions were involved in the publication: EKFZ for Digital Health at TU Dresden, University Hospital Carl Gustav Carus Dresden, Center for Scalable Data Analytics and Artificial Intelligence Dresden/Leipzig, Fraunhofer Institute for Cell Therapy and Immunology IZI (Leipzig), Institute for Clinical Immunology at University of Leipzig, University Clinic Marburg as well as the Université Paris-Saclay (Paris/France) and the life science consulting company ProductLifeGroup.

Bouchra Derraz, Gabriele Breda, Christoph Kaempf, Franziska Baenke, Fabienne Cotte, Kristin Reiche, Ulrike Köhl, Jakob Nikolas Kather, Deborah Eskenazy, Stephen Gilbert.
New regulatory thinking is needed for AI-based personalised drug and cell therapies in precision oncology.
npj Precision Oncology, 2024. doi: 10.1038/s41698-024-00517-w

Most Popular Now

AI Tool Helps Predict Relapse of Pediatr…

Artificial intelligence (AI) shows tremendous promise for analyzing vast medical imaging datasets and identifying patterns that may be missed by human observers. AI-assisted interpretation of brain scans may help improve...

NHS, Councils, and Housing could Share N…

A new technology partnership formally announced, could help NHS, local government, and housing organisations collaborate to create an unprecedented understanding of the risks and needs of people in their care...

AI-Powered Analysis of Stent Healing

Each year, more than three million people worldwide are treated with stents to open blocked blood vessels caused by heart disease. However, monitoring the healing process after implantation remains a...

Right Patient, Right Dose, Right Time

While artificial intelligence (AI) has shown promising potential, much of its use has remained theoretical or retrospective. Turning its potential into real-world healthcare outcomes, researchers at the Yong Loo Lin...

AXREM and BHTA Name Highland as 'Fu…

Hosted by trade associations AXREM and the British Healthcare Trades Association (BHTA), 'The Future of MedTech - Innovating for Tomorrow', will allow delegates to engage with speakers from the government...

Open Medical Works with Moray's Dig…

Open Medical is working with the Digital Health & Care Innovation Centre’s Rural Centre of Excellence on a referral management plan, as part of a research and development scheme to...

Generative AI on Track to Shape the Futu…

Using advanced artificial intelligence (AI), researchers have developed a novel method to make drug development faster and more efficient. In a new paper, Xia Ning, lead author of the study and...

AI could Help Improve Early Detection of…

A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center suggests that artificial intelligence (AI) could help detect interval breast cancers - those that develop between...

Building Trust in Artificial Intelligenc…

A new review, published in the peer-reviewed journal AI in Precision Oncology, explores the multifaceted reasons behind the skepticism surrounding artificial intelligence (AI) technologies in healthcare and advocates for approaches...

Siemens Healthineers infection Control S…

Klinikum Region Hannover (KRH) has commissioned Siemens Healthineers to install infection control system (ICS) at the Klinikum Siloah hospital. The ICS aims to effectively tackle nosocomial infections and increase patient...

AI Tool Uses Face Photos to Estimate Bio…

Eyes may be the window to the soul, but a person's biological age could be reflected in their facial characteristics. Investigators from Mass General Brigham developed a deep learning algorithm...

AI-Powered Precision: Unlocking the Futu…

A team of researchers from the Department of Diagnostic and Therapeutic Ultrasonography at the Tianjin Medical University Cancer Institute & Hospital, have published a review in Cancer Biology & Medicine...